The KEYNOTE-177 trial showed that pembrolizumab was more effective in treating metastatic colorectal cancer compared to chemotherapy, doubling progression-free survival in patients with microsatellite instability–high (MSI-H) mismatch repair–deficient (dMMR) subtype. The study, funded by Merck, involved 307 patients with MSI-H or dMMR mCRC who were randomly assigned to receive either pembrolizumab or chemotherapy as first-line therapy. Results were presented at the 2020 virtual annual meeting of the American Society of Clinical Oncology (abstract LBA4), demonstrating the potential of pembrolizumab as a front-line treatment for this specific subgroup of colorectal cancer patients.
Source link
Paradigm-Changing Study Results for MSI-H Metastatic CRC
